AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics (ANGO) management is scheduled to participate in the UBS and Canaccord Genuity investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
UBS Global Healthcare Conference
Fireside Chat: Monday, November 9, 2026, from 8:00-8:35 AM ET
Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Presentation: Wednesday, November 11, 2026, from 1:00-1:25 PM ET
A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261029190648/en/
Investors:
Stephen Trowbridge
Executive Vice President & CFO
518-795-1408
strowbridge@angiodynamics.com
Media:
Saleem Cheeks
Vice President, Communications
518-795-1174
scheeks@angiodynamics.com
Source: AngioDynamics, Inc.